Relationship between Polymorphisms of RR37and Sensitivity to Platinum Based Chemotherapy (GP Scheme) in Patients with Advanced Non-Small Cell Lung Cancer
|Keywords||Non-small cell lung cancer GP scheme RRM1 Polymorphism Individualized therapy|
ObjectiveCombined with clinical follow-up data, To investigate the relationshipbetween polymorphisms of RRM1(-37) and sensitivity to platinum basedChemotherapy (GP scheme) in Advanced non-small cell cancer patents.MethodsReal-time PCR using genomic DNA obtained from peripheral WBC of121advanced non-small cell cancer cases before GP Chemotherapy to detecte Thepolymorphisms of RRM1(-37).Results(1) RRM1(-37) genotype frequencies were A/C65.3%(79/121), C/C28.9%(35/121),A/A5.8%(7/121);(2)RRM1(-37) locus for the A/C short-term remission (44.3%),wassignificantly higher than that of genotype C/C or A/A patients (23.8%), thedifference was statistically significant (P﹤0.05), but the degree of nodifferentiation with NSCLC,agepathological,sex,type of independent, thedifference was not statistically significant;(P＞0.05),(3) Age, gender, KPS score of three factors on progression-free survivaltime were not significantly affected, stage of cancer patients,differentiation,and RRM1(-37) were closely related with the PFS. RRM1(-37) locus for the C/C orA/A is a risk of disease progression in patients with A/C genotype was1.625times that of patients (P<0.01);(4) Carrying RRM1(-37) genotype of chemotherapy sensitivity C/C and A/Agenotype carriers of2.406times.(P=0.042);RRM1(-37) A/C genotype in patientswith C/C and A/A genotype of the median PFS was significantly different (5.89months vs4.0months, P=0.018);(5) Carrying A/C genotype overall survival (overall survival, OS) higher thanthe C/C and A/A genotype (7.89months vs6.08months, P<0.01).ConclusionsThe polymorphisms of RR37is associated with the sensitivity to platinumbased chemotherapy in Advanced non-small cell lung cancer patients. Thedetection of RRM1genotypes is useful to indicate the therapy to platinum basedchemotherapy (GP scheme).